SecBot SecBot

EQ drug pipeline

Equillium, Inc. · 2 rated drugs
$1.06
−5.4% 1-day · Nov 20
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketUnknown — the drug is in Phase 1 healthy-volunteer testing. If successful through Phase 2 and Phase 3, potential approval would be several years away (likely 2029-2031 at the earliest).

EQ504 Updated Oct 26

What to watch

The next hard catalyst is topline Phase 1 proof-of-mechanism data in Q2 2027 (~6 months from now). Positive data showing AhR target engagement and a clean safety profile in healthy volunteers would validate the mechanism and support advancement into a Phase 2 proof-of-concept study in ulcerative colitis patients in H2 2027. Negative safety signals or failure to demonstrate target engagement would severely damage the thesis for a company now entirely dependent on EQ504 after its prior lead failed Phase 3.

Bull case
  • EQ504 targets a clinically validated pathway (AhR), the same mechanism behind indigo naturalis and VTAMA (tapinarof) in inflammatory diseases, with a novel, non-immunosuppressive approach that could differentiate it from existing UC therapies like JAK inhibitors and biologics.
  • The company has a strong cash runway into 2029 (~$57M as of June 30, 2026, plus a $20M milestone triggered by the first dosing), reducing near-term dilution risk and funding through multiple data readouts.
  • Analyst consensus is Strong Buy with a mean price target of $8.56 (595.6% implied upside from the current ~$1.12 price), reflecting optimism about the AhR mechanism and the large UC market (>$15B projected).
Bear case
  • EQ504 is a Phase 1 asset with zero clinical data in humans, the entire thesis rests on preclinical models and a mechanism that has yet to show efficacy in UC clinical trials.
  • Equillium's prior lead asset, itolizumab (EQ001), failed its Phase 3 EQUATOR study in acute GVHD (missed primary endpoint) and was rejected by the FDA for breakthrough designation, raising questions about management's drug development track record.
  • The stock trades near $1.12 with ~8.74% of shares sold short (as of Sep 30, 2026), reflecting skepticism about the company's ability to deliver value from an early-stage pipeline.
● neutral
ImpactNot rated
PhaseNot stated
Time to marketNot stated

EQ302 Updated Nov 16